Medical News / Reported from ADA: Semaglutide Significantly Reduces Long-Term Diabetes Risk Among Obesity Patients

Once-weekly 2.4 mg semaglutide is associated with an approximate 60% reduced risk of type 2 diabetes in patients with obesity, according to new findings presented at the American Diabetes Association (ADA) 2022 Scientific Sessions this weekend. In new late-breaking data presented by study author W. Timothy Garvey, MD, endocrinologist and Butterworth Professor of Medicine in the department of nutrition science at University of Alabama School of Medicine, a team of US investigators found the GLP-1 agonist provided a substantially decreased risk of type 2 diabetes development among people with obesity, regardless of their baseline glycemic status, when combined with diet and exercise. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

On-demand treatment with vonoprazan completely resolved heartburn in less than 3 hours with sustained relief for ... read more
Although the potential effects of global warming on human health continue to concern experts, the impact ... read more
Fish oil supplement intake may increase the long-term risk of atrial fibrillation (AF) in a healthy ... read more
Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19. New findings suggest full-dose ... read more